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AbstrAct
Accumulating data indicates that chromosome instability (CIN) common to cancer 
cells can be used as a target for cancer therapy. At present the rate of chromosome 
mis-segregation is quantified by laborious techniques such as coupling clonal cell 
analysis with karyotyping or fluorescence in situ hybridization (FISH). Recently, a 
novel assay was developed based on the loss of a non-essential human artificial 
chromosome (HAC) carrying a constitutively expressed EGFP transgene (“loss of 
signal” assay). Using this system, anticancer drugs can be easily ranked on by their 
effect on HAC loss. However, it is problematic to covert this “loss of signal” assay into 
a high-throughput screen to identify drugs and mutations that increase CIN levels. 
To address this point, we re-designed the HAC-based assay.  In this new system, the 
HAC carries a constitutively expressed shRNA against the EGFP transgene integrated 
into human genome. Thus, cells that inherit the HAC display no green fluorescence, 
while cells lacking the HAC do. We verified the accuracy of this “gain of signal” assay 
by measuring the level of CIN induced by known antimitotic drugs and added to the 
list of previously ranked CIN inducing compounds, two newly characterized inhibitors 
of the centromere-associated protein CENP-E, PF-2771 and GSK923295 that exhibit 
the highest effect on chromosome instability measured to date. The “gain of signal” 
assay was also sensitive enough to detect increase of CIN after siRNA depletion of 
known genes controlling mitotic progression through distinct mechanisms. Hence 
this assay can be utilized in future experiments to uncover novel human CIN genes, 
which will provide novel insight into the pathogenesis of cancer. Also described is 
the possible conversion of this new assay into a high-throughput screen using a 
fluorescence microplate reader to characterize chemical libraries and identify new 
conditions that modulate CIN level.
INtrODUctION
Abnormal chromosome number (aneuploidy) 
is a known feature of most solid tumors and is often 
accompanied by an elevated rate of chromosome mis-
segregation termed chromosome instability (CIN) [1]. The 
gain or loss of entire chromosomes leads to large-scale 
changes in gene copy number and expression levels. The 
molecular mechanisms underlying CIN include defects 
in chromosome cohesion, mitotic checkpoint function, 
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kinetochore-microtubule attachment dynamics, cell cycle 
regulation as well as defects in DNA replication. Mutations 
in CIN genes are thought to be an early event in tumor 
development, predisposing cells to the accumulation of 
genetic changes leading to progression to a cancerous state 
[2-4]. Notably, a significant fraction of human CIN genes 
remains unidentified and in part this is due to the lack of 
a simple assay to detect CIN in vertebrate cells, similar 
to that developed for yeast cells [5]. Thus, there is an 
important need to develop improved assays for measuring 
chromosome transmission fidelity in human cells.
While CIN can drive cancer genome evolution and 
tumor progression, recent findings point to the existence 
of a threshold level beyond which CIN becomes a 
barrier to tumor growth. Therefore excessive CIN can be 
exploited therapeutically [6-11] and evaluation of CIN 
as an approach to cancer therapy is an attractive strategy. 
However, drugs known to increase CIN beyond the 
therapeutic threshold are currently few in number. Hence, 
a screen of established anticancer drugs as well as novel 
drugs to rank their CIN potency is warranted. 
Typically, rates of chromosome mis-segregation 
have been quantified by laborious techniques such 
as coupling clonal cell analysis with karyotyping or 
fluorescence in situ hybridization (FISH) [12-14] In 
our recent work, we developed a quantitative assay for 
measuring CIN [15] that is based on the use of a non-
essential human artificial chromosome (HAC) with a 
functional kinetochore [16-20] . Specifically we used a 
HAC constructed for gene delivery that contains a single 
gene-loading site [21-23]. To adapt this HAC for CIN 
studies, a constitutively expressed EGFP transgene was 
inserted into it [15]. Cells that inherit the HAC display 
green fluorescence, while cells lacking the HAC do not 
(“loss of signal” assay). This allows the measurement of 
HAC loss rate by routine flow cytometry (details of this 
assay are shown in Supplementary Figure S1). 
There are several advantages of the HAC-based 
assay compared to karyotype analysis or micronucleus 
tests that are commonly used to study CIN and its 
induction by environmental agents. First, the HAC-based 
assay is significantly faster and less labor intensive. 
Second, the flow cytometer can readily analyze tens of 
thousands of cells compared to the hundred or so cells the 
latter two methods can analyze. Thus, the measurements 
are more precise. Finally, while the HAC contains a 
functional centromere/kinetochore and is efficiently 
transferred at mitosis, its relatively small size (~1 Mb) 
[24] causes a frequency of spontaneous HAC loss roughly 
10-fold higher than that of native chromosomes [15, 16], 
making the HAC a sensitized model for measuring CIN. 
Together, these features of the HAC allow detection of 
small differences between frequencies of chromosome 
loss induced by different compounds. This is important 
because accurate assessment of CIN is crucial to select 
drugs with the highest effect on chromosome transmission. 
In our recent study, the EGFP-HAC-based CIN assay was 
applied for analysis of 62 anticancer drugs corresponding 
to six groups of compounds with different mechanisms of 
action [25]. Within each group, drugs could be ranked with 
regards to their effect on the rate of HAC loss [25]. 
While EGFP-HAC offers sensitive, precise and 
simple means to measure CIN, development of a fast 
high-throughput screening method, based on the detection 
of fluorescence signal loss is problematic. This is mostly 
due to the difficulty to detect single cells with a decreased 
EGFP signal among the large number of the EGFP-positive 
cells during the first days after drug treatment. Herein, we 
developed a complementary HAC-based system, based 
on the gain of the EGFP fluorescence signal after HAC 
loss. In this system, the HAC carries a constitutively 
expressed shRNA against an EGFP transgene integrated 
elsewhere into a natural human chromosome. Thus, cells 
that inherit the HAC display no green fluorescence, while 
cells lacking the HAC do. The high precision of this new 
assay was verified by measuring HAC loss after cell 
treatment by several anticancer drugs corresponding to 
three groups of compounds with different mechanisms of 
CIN induction. In addition, both HAC-based assays have 
been proven to be applicable for screening human genes 
to identify phenotypes associated with CIN and thus to 
identify CIN genes themselves. 
rEsULts
Experimental design for quantitative cIN 
measurement by “gain of signal” assay
Figure 1A shows the general scheme of the “gain 
of signal” assay developed for measuring chromosome 
instability (CIN) using a genetically marked human 
artificial chromosome (HAC). The EGFP (enhanced 
green fluorescence protein) transgene is integrated into a 
random chromosomal site of human HT1080 cells and is 
expressed, making the cells green (I) (Figure 1A and 1B). 
The HAC developed in hamster host CHO cells carries 
the mCherryFP (mCherry fluorescence protein) transgene 
and a constitutively expressed short hairpin RNA (shRNA) 
against EGFP. After transfer of the mCherry-shRNA-
HAC into HT1080-EGFP-expressing cells, the HAC is 
maintained as a non-essential 47th chromosome (II) due 
to the presence of its functional kinetochore and the cells 
maintaining the HAC become red (II) (Figure 1A and 1B). 
Normally, after growing in non-selective medium (-BS) 
(i.e. in the absence of selection for HAC), the majority of 
cells still retain the HAC (natural HAC loss). However, if 
proper chromosome transmission is impaired, the fraction 
of cells that lost the HAC is significantly increased. 
Thus, while the control untreated cells do not display 
green fluorescence the cells that have lost HAC after 
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drug treatment (induced HAC loss) should exhibit green 
fluorescence (III) that can be detected by fluorescence 
microscopy or flow cytometry (Figure 1A and 1B). In 
principle, this new assay may provide a convenient and 
sensitive way to monitor CIN in human cells.
construction of a cell line for cIN phenotype 
screening
To adapt the alphoidtetO-HAC [16] for CIN 
studies, the tDNA-shEGFP-mCherry plasmid (A245) 
(Supplementary Figure S2) was inserted into a single 
loxP loading site of the HAC [22] in HPRT-deficient 
Chinese hamster ovary (CHO) cells (Figure 2A). In the 
A245 construct, the mCherry-shRNA cassette is flanked 
by tDNA insulator sequences to protect the transgene from 
epigenetic silencing [26, 27]. Targeting of the cassette into 
the loxP site was accompanied by reconstitution of the 
HPRT gene, allowing cell selection on HAT medium. PCR 
analysis with specific primers (Supplementary Table S1) 
confirmed that the HPRT gene was indeed reconstituted 
in five randomly chosen drug-resistant clones. Based on 
fluorescence microscopy, all clones expressed mCherry. 
FISH analysis of CHO metaphase spreads revealed the 
HAC in an autonomous form in three analyzed clones 
Figure 1: “Gain of signal” HAc-based assay to measure cIN level in cancer cells. A. A general scheme of assay to measure 
chromosome instability (CIN), based on the HAC expressing a small hairpin RNA (shRNA) against the EGFP transgene integrated into 
a random chromosomal site of genome of the HT1080 human cell line. When EGFP is expressed it makes the cell green. Cells containing 
the mCherry-shRNA-HAC display a red signal. When cells loose the HAC, they become green again. Thus, it is expected that the control 
population of untreated cells show uniform red fluorescence while cell population that have lost HAC after drug treatment should show 
green fluorescence. The percentage of cells with EGFP expressed can be measured by FACS. Thus, the compounds, which increase HAC 
loss and, therefore, increase spontaneous chromosome mis-segregation rates, may be identified. b. Fluorescence images of human HT1080 
cells expressing the EGFP transgene (exhibiting a green fluorescent signal) (I); the cells after transfer into them the mCherry-shRNA-HAC 
(exhibiting a red fluorescent signal) (II) and the same cells that have lost the HAC after drug treatment (exhibiting a green fluorescent 
signal) (III). FISH analysis of the HAC-containing HT1080 clone is also shown. The HAC was visualized using the BAC32-2-mer(tetO) 
DNA probe (red) (see for details MATERIALS AND METHODS). 
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(Supplementary Figure S3). One clone was chosen for 
further experiments.
The mCherry-shRNA-HAC was transferred from 
hamster CHO to the human HT1080 cells in which 
the EGFP transgene (plasmid A158) (Supplementary 
Figure S4) was integrated into a random chromosome 
site providing stable expression of the EGFP protein 
(clone HT1080-JH1) (Figure 2A). The HAC transfer 
was performed via microcell-mediated chromosome 
transfer (MMCT). Recipient cells were selected using 
the BS resistance gene on the alphoidtetO-HAC [16]. 
Three BS-resistant clones were isolated from one MMCT 
experiment and all three exhibited barely detectable 
expression of EGFP, indicating transgene silencing 
induced by the shRNA. FISH analysis showed that the 
HAC was maintained autonomously without detectable 
integration into the host genome in two out of three 
selected clones (Supplementary Figure S5A). One clone 
containing the mCherry-shRNA-HAC (clone HT1080-
shGFP-4) was chosen for further analysis. In this clone, 
EGFP silencing was stable for at least six months under 
selective conditions (i.e. under selection for BS). Rare 
events of spontaneous HAC loss were accompanied by 
visual expression of EGFP. Based on these results, we 
conclude that the mCherry-shRNA is stably expressed 
from the HAC and that these cells may be exploited as 
a sensitized system for analyzing chromosome stability. 
Quantitative profiling of CIN induced through 
treatment by anticancer agents
We next investigated whether the mCherry-
shRNA-HAC-based assay could be used to quantify the 
effects of compounds that cause chromosome loss or 
mis-segregation. For this purpose, we first chose seven 
anticancer drugs that have been previously ranked on their 
effects on HAC loss in HT1080 cells using the original 
“loss of signal” EGFP-HAC-based system (Supplementary 
Figure S1) [15, 25]. The cells with the autonomously 
propagated mCherry-shRNA-HAC were treated with two 
known aneugens: taxol (paclitaxel) and nocodazole, two 
HDAC inhibitors: romidepsin and SAHA, the poly(ADP-
ribose) polymerase (PARP) inhibitor: olaparib, and the 
topoisomerase I inhibitor: LMP400. 
For each compound, a cell cytotoxicity assay was 
carried out to determine IC50 values, i.e., the conditions 
under which the viability of cells would be around 50%. 
This parameter was chosen in order to normalize the 
results at the same percentage of viable cells [15]. Time 
treatments and drug concentrations corresponding to 
the IC50 are summarized in Table 1. After treatment, 
table 1: List of compounds used in this study
Drugs* target Ic50**
Taxol Microtubule Stabilizing 10 nM
Nocadazole Microtubule Destabilizing 5 µM
SAHA Histone Deacetylase 2 µM
Romidepsin Histone Deacetylase 2 nM
Olaparib Poly ADP Ribose Polymerase 10 µM
LMP400 Topoisomerase I 50 nM
Gemcitabine Ribonucleotide Reductase 50 nM
PF-2771 CENP-E 10 µM
GSK923295*** CENP-E 10 µM
Zoledronic acid CENP-F 10 µM  
sirNA target sense sequence as ordered**** sirNA per well(6-well plate)
SKA3 5′- AGACAAACAUGAACAUUAAUU -3′ 25 pmol
CENP-E 5′- AACACGGAUGCUGGUGACCUC -3′ 25 pmol
MIS18β 5′- AGGCAGUACUUACAACCUUUU -3′ 25 pmol
ON-TAGET plus, Non-
targeting pool
5′- UGGUUUACAUGUCGACUAA -3′
5′- UGGUUUACAUGUUGUGUGA -3′
5′- UGGUUUACAUGUUUUCUGA -3′
5′- UGGUUUACAUGUUUUCCUA -3′
25 pmol
*All drugs, except RF-1771, GSK92395 and zoledronic acid, were described in our previous publications [15, 25]. GSK92395 
was purchased from Selleckchem (Catalog no. S7090).  PF-1771 was kindly provided by Dr. B.W. Murray (Pfizer Worldwide 
Research and Development, La Jolla Laboratories, San Diego). Zoledronic acid was purchased from Novartis Pharma AG 
(Stein, Switzerland).  
**The cells were treated overnight.
*** For HT1080 cells containing EGFP-HAC, IC50 for GSK923295 was 2 µM. For HT1080 cells containing mCherry-
shRNA-HAC, IC50 was 10 µM.
****The two underlined uracil (UU) were added by Dharmacon as part of siRNA construction. 
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the cells were grown for two weeks in the absence of 
selection. Samples were analyzed every few days, and 
the proportion of fluorescent cells was determined by 
FACS. Green-fluorescent cells could be detected after a 
few days, and treated and untreated cell populations were 
clearly distinguishable after 5-7 days. The delay between 
HAC loss and the appearance of non-fluorescent cells is 
due to the persistence of the shRNA against EGFP. The 
sampling time had a broad interval (5-14 days) without 
a significant affect on the calculated rate of HAC loss 
Figure 2: Development of “gain of signal” assay and its actual application for drugs screening. A. General steps of 
development of “gain of signal” HAC-based assay. First, the EGFP transgene (plasmid A158) was integrated into a random chromosome 
site in human HT1080 cells, providing a stable expression of the EGFP protein (cells are green). Separately, the tDNA-shEGFP-mCherry 
plasmid (A245) was inserted into a unique gene-loading loxP site of alphoidtetO-HAC propagated in hamster CHO cells (cells are red). Then 
alphoidtetO-HAC carrying a constitutively expressed shRNA against EGFP was transferred into human HT1080 cells with the integrated 
EGFP transgene. After HAC transfer and shRNA expressed, the EGFP transgene is silenced and the cells become red. b. Flow cytometry 
histograms illustrating EGFP fluorescence before and after drug treatment. The x-axis represents the intensity of the fluorescence, the y-axis 
the number of cells. The results of triplicate experiments are shown.
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similar to that previously determined for the original “loss 
of signal” system [15, 25]. Figure 2B shows representative 
flow cytometry histograms illustrating a gain of green 
fluorescence in cell populations treated by a single doze 
of taxol or gemcitabine. Importantly, the measurements 
were highly reproducible: the raw FACS data of three 
independent populations for drug treatments have standard 
deviations less than 1%.
FISH analysis was used to confirm that the 
appearance of fluorescent cells detected by flow cytometry 
corresponded to HAC loss (Supplementary Figure S5). 
Quantitative analysis of metaphase chromosome spreads 
using a HAC-specific probe (see MATERIALS AND 
METHODS) correlated with the data on HAC loss 
determined by FACS (see Supplementary Table S2). 
Therefore, we conclude that the appearance of green 
fluorescent cells is caused by HAC loss. 
Figure 3A summarizes the estimated rates of HAC 
loss in response to the analyzed drugs. The rate of HAC 
loss (RDrug) induced by drug treatment was calculated from 
the proportion of fluorescent cells in the population (see 
MATERIALS AND METHODS). The data reveal that 
the drugs affect the rates of HAC mis-segregation during 
mitotic divisions differently. The highest effect for this 
group of established drugs was detected for taxol and 
gemcitabine. A single dose of these drugs increased the 
rate of HAC loss ~40 and 50 fold, respectively. To verify 
the accuracy of measuring HAC loss using this “gain of 
signal” system, in parallel experiments the effect of the 
same compounds was measured using the original “loss of 
signal” system. The results of this analysis are presented in 
Figure 3B and clearly demonstrate that ranking the drugs 
according to their effect on HAC loss using two different 
systems is indistinguishable. 
Drugs known to increase CIN beyond the 
therapeutic threshold are currently few in number, and the 
clinical promise of targeting the CIN phenotype warrants 
new screening efforts. Taking this in account, in this 
work we analyzed three new promising anticancer drugs, 
PF-2771 and GSK923295 [28] that are inhibitors of the 
centromere-associated protein CENP-E [29]. (CENP-E 
is a microtubule plus-end-directed kinetochore motor 
required for congression of pole-proximal chromosomes 
[30]) and a potential inhibitor of the kinetochore protein 
CENP-F, zoledronic acid [31]. Therefore, these inhibitors 
might induce a high rate of chromosome mis-segregation. 
Indeed, treatment of cells by PF-2771 and GSK923295 
increased the rate of HAC loss to values equal to or 
exceeding those observed after taxol or gemcitabine 
treatment (Figure 3A and 3B). Note, these two compounds 
exhibited the highest effect on HAC loss based on a 
ranking of 62 anticancer compounds [25]. 
We conclude that this new “gain of signal” assay is 
suitable for comparing the effect of various drugs on CIN. 
Quantitative profiling of CIN induced by gene 
knockouts
One difficulty in identifying mammalian CIN 
regulators and determining their relative importance in 
cancer is the lack of a straightforward quantitative assay 
for CIN in live mammalian cells. To address this point, we 
analyzed whether the new “gain of signal” system could 
be applied for detection of CIN induced by the knockout 
of genes controlling mitotic progression through distinct 
mechanisms. We performed the experiments on measuring 
the HAC stability after siRNA depletion of three proteins: 
the CENP-A loading cofactor MIS18β, the centromere-
associated protein CENP-E and a spindle/kinetochore-
associated protein SKA3/RAMA1 [29, 32-35]. As seen 
in Figure 3C, depletion of MIS18β or SKA3/RAMA1 
protein significantly increased the frequency of HAC 
loss. No detectable destabilization of HAC was observed 
after cell treatment by control siRNA. Control Western 
blots showed a decrease of corresponding proteins in the 
treated cells (Supplementary Figure S6). FISH analysis 
of metaphase chromosome spreads using a HAC-specific 
probe correlated with the data on HAC loss determined 
by FACS (Supplementary Table S2). A similar effect 
of depletion of the same genes was detected using the 
original “loss of signal” system (Figure 3D). Collectively, 
the above results validate the ability of both HAC-based 
assays to be employed for identification of novel genes 
controlling chromosome transmission in human cells.
Quantitative profiling of CIN inducing drugs by a 
fluorescence microplate reader
In order to efficiently search chemical or siRNA 
libraries for drugs or gene knockouts inducing CIN, it is 
necessary to develop a high-throughput screen (Figure 
4A). To that end, we performed a set of pilot experiments. 
First, we demonstrated that it is possible to construct 
a titter curve using microplate reader data of EGFP 
fluorescence from populations of known composition of 
HAC-containing (not green) and HAC-less (green) cells. A 
titter curve was generated by mixing two cell populations, 
the HT1080-shGFP-4 cell line which contains the HAC 
(not green), and the HT1080-JH1 expressing EGFP and 
without HAC (green) in varying compositions ranging 
from 0% to 100%. The green fluorescence of these mixed 
populations was determined with a microplate reader 
(Figure 4B and 4C). Using the standard deviation of the 
plate reader data, we found that a significant difference at 
(P < 0.01) could be detected if the rate of HAC loss per cell 
division of two drug treatments differed by 0.23 (Figure 
4D-4F) (see for details MATERIAL AND METHODS). 
This resolution is insufficient to rank drugs against one 
another. However, it is sufficient to grade candidate CIN 
drugs into 4 broad categories (Figure 4G). The standard 
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Figure 3: Measurements of cIN induced through treatment by anticancer agents or gene knockouts. A., b. Effect of 
anticancer drugs on CIN was measured by “gain of signal” and “loss of signal” HAC-based assays. HT1080 cells containing either the 
mCherry-shRNA-HAC or EGFP-HAC were treated by ten different compounds as described in MATERIALS AND METHODS. The rate 
of HAC loss per cell division was calculated based on the ratio of HAC-positive, HAC-negative cells and the average time per cell division. 
The drug concentrations used were at IC50 for HT1080 cells. The strongest CIN inducers identified were gemcitabine, taxol, PF-2771 and 
GSK923295. The control corresponds to the frequency of spontaneous HAC loss in HT1080 cells. c., D. Effect of gene knockouts on the 
rate of HAC loss. HT1080 cells carrying either the mCherry-shRNA-HAC or EGFP-HAC were treated by different siRNAs and the rate 
of HAC loss per generation was calculated as described in MATERIALS AND METHODS. In both systems, the strongest CIN effect was 
observed after cells treatment with MIS18β siRNA. The control corresponds to a frequency of HAC loss after treatment by a negative 
control siRNA. 
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deviation in the calculated rate of HAC loss was found 
to be proportional to . Thus, better resolution between 
candidate drugs can be obtained by either decreasing the 
standard deviation (σ) of the microplate readings or by 
increasing the difference in green fluorescence intensity 
between HAC-less cells and HAC-containing cells (m).
Then we analyzed three anticancer drugs, PF-2771, 
GSK923295 and zoledronic acid, using a microplate 
reader. As seen from Figure 5, treatment of HAC-
containing cells by PF-2771 or GSK923295 experienced a 
dramatic increase in the rates of HAC loss (Figure 5C and 
5D) that could be quantified by a fluorescence microplate 
reader (Figure 5B). Thus, the “gain of signal assay” may 
be adapted to a 96-well microplate format and used to 
detect the fluorescence after treatment by a compound. 
DIscUssION
Most solid tumors are aneuploid, carrying an 
abnormal number of chromosomes, and they frequently 
mis-segregate whole chromosomes in a phenomenon 
termed chromosome instability (CIN). Despite its 
importance in cancer etiology and therapy, until recently 
there were no fast, straightforward, quantitative assays 
for CIN. To address this problem, previously we 
developed quantitative CIN assay based on a Human 
Artificial Chromosome (HAC) carrying a constitutively 
expressed EGFP transgene [15]. In this assay, HAC loss 
events induced by drug treatment could be measured as 
the fraction of cells that lose EGFP fluorescence signal 
using routine flow cytometry. This “loss of signal” assay 
is simple and reproducible and it was successfully used 
to rank a set of different compounds for their effect on 
CIN [25]. Unfortunately, this assay is not suitable for the 
development of a high-throughput screening method. It is 
difficult to detect the loss of EGFP fluorescence in a few 
cells against a bright background of EGFP-positive cells. 
However the opposite, the gain of EGFP fluorescence 
against a background of colorless cells is much easier 
to detect. Thus, an assay based on “gain of signal” 
would potentially be more suitable for high-throughput 
screening and perhaps earlier detection of the induced CIN 
phenotype. 
In this report, we have described the development 
and validation of a novel quantitative HAC-based assay 
for assessing chromosome stability in human cells. A 
key design feature of this assay is that the fluorescence 
signal is gained in the cells after loss of a HAC that carries 
a constitutively expressed shRNA against an EGFP 
transgene integrated elsewhere into the human genome. 
Thus, cells that inherit the HAC do not display green 
fluorescence, while cells lacking the HAC do. To verify 
the accuracy of this new assay, in parallel experiments 
we measured the rates of HAC loss in a response to cells 
treatment by a set of anticancer drugs using “gain of 
signal” and “loss of signal” systems with flow cytometry 
as a read-out. The relative ranking of drugs that strongly 
induced CIN did not change, although the same could 
not be said for drugs that weakly induced CIN. As the 
aims of this system was to identify drugs that strongly 
induced CIN, the new “gain of signal” assay may be 
used both for ranking drugs on their effect on CIN and 
also for identifying new compounds that promote CIN. 
During these experiments we identified two drugs, i.e. the 
newly developed inhibitors of the centromere-associated 
protein CENP-E, PF-2771 and GSK923295, which induce 
an extremely high rate of HAC loss. These compounds 
along with several other drugs that greatly increase CIN, 
including paclitaxel, olaparib, talazoparib, LMP400 and 
gemcitabine [25], may be considered as a first choice 
when CIN is considered as a target for cancer therapy. 
In addition, we demonstrated that both HAC-based 
systems, i.e. “loss of signal” and “gain of signal”, are 
sensitive enough for detection of CIN induced by depletion 
of genes, for example, controlling mitotic progression 
through distinct mechanisms. We demonstrated that siRNA 
depletion of two genes, MIS18β and SKA3/RAMA1, was 
accompanied by HAC destabilization to a greater or lesser 
extent. At present, approximately 400 human genes which 
control transmission of chromosomes have been annotated 
with gene ontology (GO) terms, while systematic CIN 
gene screens in yeast have revealed 692 genes [5]. 
Therefore, in the future these HAC-based assays may be 
useful in genome-wide screening to uncover novel CIN 
genes in humans. The identification of a comprehensive 
set of genes controlling chromosome segregation should 
expedite the development of new therapeutic strategies to 
target the CIN phenotype of cancer cells.
We also examined the potential of the HAC-
based “gain of signal” assay in a high-throughput screen 
of chemical libraries and identification of new genes 
that modulate CIN (e.g. using multiple gene depletion 
screens). The pilot experiments were performed where we 
combined the assay with a 96-well fluorescence microplate 
reader (see Figures 4 and 5). Although the fluorescence 
microplate reader was far less sensitive than the flow 
cytometer, we were able to broadly quantify CIN inducing 
drugs into 4 categories (Negligible, Moderate, High and 
Very High) and quantitatively distinguish the drugs by a 
fluorescence microplate reader. 
It is worth noting that this method has some 
limitations due to the fluorescence signals detection. We 
expect to improve the present assay by: i) increasing the 
expression of the EGFP transgene by generating new 
HAC-host cell lines with EGFP integrated into different 
chromosomal sites; ii) expressing multiple shRNA 
targeted to different parts of the EGFP mRNA and, thus, 
improving silencing; iii) reengineering the mCherry to 
be constitutively expressed and act as a marker for cell 
density. In addition, the sensitivity of the assay may 
be significantly improved using another plate reader 
system for detection of a fluorescence signal. This work 
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Figure 4: A. Scheme of a high throughput assay for measuring chromosome instability (CIN). During S-phase the HAC is duplicated 
in the cell as other host chromosomes. Under normal growth conditions (control), after cell division the majority of cells in population 
contain the HAC (1:1 segregation). After drug or siRNA treatment, one copy of HAC can be lost during cell division (1:0 segregation) 
or two copies of HAC can mis-segregate (2:0 segregation). The cells that inherited the HAC are fluorescent red while cells that lost it are 
fluorescent green. For each treatment, the average fluorescence of each cell sample may be measured using a multi-well plate reader. Thus, 
the genes involved in chromosome transmission or drugs affecting chromosome stability may be identified. b. An example of a titration 
curve between EGFP intensity against cell populations of varying percentage of HAC-containing (not green) and HAC-less (green) cells 
obtained from a fluorescence microtiter plate reader. c. Construction of a linear curve between a cell population’s EGFP intensity against 
the percentage of HAC-containing cells. D. The relationship between the standard deviation of a cell population’s EGFP intensity and it’s 
percentage of HAC-containing cells. E. The relationship between the standard deviation of HAC-containing cells and the ‘rate of HAC 
loss per cell division’. F. The estimated standard deviation in the ‘rate of HAC loss’ using data derived from a fluorescence plate reader and 
known rates of natural HAC loss. G. The minimum difference between two values of ‘HAC loss’ needed to be significant (P < 0.01) was 
calculated using a T-test and the standard deviations derived above. The results indicate that plate reader is only able to discriminate drugs 
into broad categories.
Oncotarget14850www.impactjournals.com/oncotarget
Figure 5: A. An illustration of how a 96-well plate was loaded with drug treated cells. Populations of known mixtures of HT1080-
shGFP-4 (HAC+) and HT1080-JH1 (HAC-) cells were included as a ladder. b. The calculated rates of HAC loss per cell division for three 
drugs, zoledronic acid, PF-2771 and GSK923295, using the “gain of signal” system with a fluorescence microtitter plate reader. c. The 
calculated rates of HAC loss for the same drugs using the “gain of signal” system with FACS. D. The calculated rates of HAC loss for the 
same drugs using the ”loss of signal’ system with FACS.
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is currently in progress. Also, the current labeling of the 
HAC does not allow us to simply distinguish between 
HAC loss (1:0) and HAC mis-segregation (2:0) events. 
(It is possible only by using a time-consuming interphase 
FISH). In principle, this limitation may be overcome by 
expression of the tetracycline repressor fused to mCherry 
(TetR-mCherry). In such cells the alphoidtetO-HAC may 
be monitored the live following TetR-mCherry signal. 
Alternative may be loading a copy number dependent, 
selectable marker (e.g. the dihydrofolate reductase gene) 
into the HAC where an increased copy number of this 
gene is accompanied by a higher resistance of cells to 
methotrexate. 
To summarize, a novel “gain of signal” HAC-based 
assay allows straightforward, quantitative assessment 
of CIN under a variety of conditions. The assay will 
be employed to identify novel agents that specifically 
elevate chromosome mis-segregation and drive lethal 
aneuploidy. The assay is also suitable for synthetic lethal 
screens in which combinatorial effects of disruption of 
two or more pathways can be studied. In future, this “gain 
of signal” assay may be adapted for high-throughput 
chemical screens using a fluorescence microplate reader to 
characterize chemical libraries and identify new conditions 
that modulate CIN levels, thereby laying the foundation 
for new treatment strategies for cancer. 
MAtErIALs AND MEtHODs
cell lines and culture
Human fibrosarcoma HT1080 cells were 
cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) (Invitrogen) supplemented with 10% (v/v) 
tet system-approved fetal bovine serum (Clontech 
Laboratories, Inc.) at 37ºC in 5% CO2. Hypoxanthine 
phosphoribosyltransferase (HPRT)-deficient Chinese 
hamster ovary (CHO) cells (JCRB0218) carrying the 
alphoidtetO-HAC [22, 24, 25] were maintained in Ham’s 
F-12 nutrient mixture (Invitrogen) plus 10% FBS with 8 
µg/ml of BS (Funakoshi). After loading of the mCherry-
shRNA cassette (see below) into the alphoidtetO-HAC, 
the CHO cells were cultured in 1× HAT supplemented 
medium. 
construction of the tDNA- mcherry- shrNA 
plasmid (A245)
Scheme of construction of the A245 plasmid is 
presented in Supplementary Figure S2. This plasmid was 
constructed in three steps. In step 1, the HuSH pGFP-
V-RS plasmid (OriGene) was digested with BamHI /
HindIII and the shGFP sequence was ligated in as a 
double stranded oligo formed by annealing primers J001 
and J002. The plasmid created was HuSH-pRS-shGFP. 
In step 2, the pcDNA 3.1(+) (Thermofisher Scientific) 
was digested with HindIII and XbaI. Then the mCherry 
fragment was PCR amplified from the pRSET-B-mCherry 
plasmid (Tsien Lab, University of California, San Diego) 
using the primers J005 and J006, digested with HindIII 
and XbaI. The two fragments were ligated, creating the 
plasmid pcDNA-mCherry. In step 3, the A245 plasmid 
was completed in a 3-way ligation of the following 
fragments: the U6-shGFP fragment, obtained by PCR 
amplification of HuSH-pRS-shGFP plasmid using the 
primers J003 and J004, followed by digestion with SpeI 
and XhoI; the tDNA-loxP-3’HPRT fragment, obtained by 
SpeI / BamHI digest of the CAG-EGFP-tDNA plasmid 
[26]; and lastly the CMV-mCherry-BGHpA fragment 
which was obtained by PCR amplification of pcDNA-
mCherry using the primers J007 and J008, followed by 
digestion with XhoI and BamHI. Sequences of all primers 
used are in Supplementary Table S1.
construction of the tDNA-EGFP-HytK plasmid 
(A158)
Scheme of construction of the plasmid A158 is 
presented in Supplementary Figure S4. The plasmid A158 
was constructed in three steps. In step 1, the plasmid A154 
was constructed in a 3-way ligation of three fragments: 
the tDNA-CAG fragment, obtained from EcoRI/SacI 
digestion of the CAG-EGFP-tDNA plasmid [26]; the 
pBS backbone, obtained from SacI / BamHI digestion of 
pBlueScript II KS (Stratagene); and the EGFP fragment, 
obtained by PCR amplification of the plasmid p264 [22] 
using the primers B119/B052, followed by BamHI/ EcoRI 
digestion. In step 2, the plasmid A156 was constructed 
in a 3-way ligation of three fragments: the T2A-HyTK 
fragment, obtained from BamHI /XhoI digestion of the 
CAG-attB-HyTK plasmid [36]; the tDNA-P fragment, 
obtained by PCR amplification of pCR4-TOPO-tDNA 
[27] using the primers B405 / B404 followed by SalI / 
NotI digestion; and the pBS backbone, obtained by NotI 
/BamHI digestion of pBlueScript II KS (Stratagene). 
In step3, the A158 plasmid was completed in a 3-way 
ligation of the following three fragments: the tDNA-CAG-
EGFP fragment was obtained by SacI /BamHI digestion 
of the plasmid A154; the T2A-HyTK-tDNA fragment was 
obtained by BamHI / NotI digestion of the A156 plasmid; 
and the pBS backbone was obtained by PCR amplification 
of pBlueScript II KS (Stratagene) using the primers B396/
B395 followed by digestion with NotI / SacI. Sequences of 
all primers used are in Supplementary Table S1.
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Loading of the tDNA-mcherry-shrNA plasmid 
into the loxP site of alphoidtetO-HAc in hamster 
cHO cells
3 μg of the A245 plasmid and 1 μg of the Cre 
expression pCpG-iCre vector DNA were co-transformed 
into HPRT-deficient hamster CHO cells containing 
the alphoidtetO-HAC by lipofection with FuGENEHD 
transfection reagent (Roche) or Lipofectamine 2000 
(Invitrogen). HPRT-positive colonies were selected after 2 
to 3 weeks growth in HAT medium. For each experiment, 
from 5 to 7 clones were usually selected. Correct loading 
of the A245 plasmid into the HAC was confirmed by 
genomic PCR [26] with a specific pair of primers that 
diagnose reconstitution of the HPRT gene (Supplementary 
Table S1). 
Generation of the EGFP-expressing human cell 
line
The EGFP-containing plasmid A158 was linearized 
with ScaI and transfected into HT1080 cells. Transfectants 
were selected on DMEM plus FBS medium with 80 μg 
/ml Hygromycin B (Invitrogen, USA). Of the colonies 
obtained, the clone HT1080-JH1 exhibited the strongest 
expression of EGFP was chosen for further experiments to 
host the HAC that constitutively expressed shRNA against 
EGFP. 
Microcell-mediated chromosome transfer
The alphoidtetO-HAC containing the mCherry-
shRNA cassette was transferred from hamster CHO cells 
to the human HT1080-JH1 cell line using a standard 
microcell-mediated chromosome transfer (MMCT) 
protocol [22, 37]. 12 µg/ml blasticidin (BS) was used to 
select resistant colonies containing the HAC. Typically, 
three to ten BSR colonies are obtained in one MMCT 
experiment. BSR colonies were analyzed by FISH for 
the presence of the autonomous form of the HAC. 
The potential co-transfer of CHO chromosomes was 
excluded using a sensitive PCR test for rodent-specific 
SINE elements (Supplementary Table S1). The clone 
HT1080-shGFP-4 was selected for further work and was 
maintained under selection with 12 µg/ml blasticidin and 
80 µg/ml hygromycin B.
Flow cytometry
Analysis of EGFP expression was performed using 
LSRFortessa (BD Biosciences) flow cyctometer and 
BD FACSDiva software [15]. The cells were harvested 
by trypsin-treatment. Intensities of fluorescence were 
determined by flow cytometry. 1.0 x 104 cells were 
analyzed for each cell sample. 
Drug treatment
Ten different drugs were used in our experiments 
(Table 1). The experiment protocol was as follows. 
HT1080 cells containing EGFP-HAC were maintained 
on 6 µg/ml blasticidin selection while HT1080 cells 
containing mCherry-shRNA-HAC was maintained 
on 12 µg/ml blasticidin and 80 µg/ml hygromycin B. 
Approximately 1 × 105 cells were cultured either in the 
presence or absence of blasticidin selection in parallel 
with a third culture that was exposed to the agent under 
examination to test its effect on HAC segregation. The 
drug concentration applied was adjusted to the IC50 
level for each compound which was determined using 
a proliferation assay described below. Concentrations 
of drugs and lengths of treatment are presented in Table 
1. Subsequently, the drug was removed by performing 
three consecutive medium washes and the cells were 
subsequently grown without antibiotic selection for 13 
days. At the end of the experiment, cells were collected 
and analyzed by flow cytometry to detect the proportion 
of cells that gain or loss EGFP fluorescence. This served 
as a measure of HAC stability following drug treatment. 
For all drugs, experiments were carried out in triplicate. 
treatment by sirNAs
SKA3/RAMA1, MIS18β and CENP-E were depleted 
using established siRNAs targeting published sequences 
[29, 32-34]. siRNAs used to target SKA3, CENP-E and 
MIS18β are listed in Table 1. siRNAs were purchased 
from Dharmacon (Lafayette, CO). For siRNA treatment, 
1x105 / well cells were seeded in 6 well plates before a 
day of the experiment. Cells were transfected with each 
siRNAs using lipofectamine-RNAiMAX (Invitrogen). 
Cells were grown without blasticidine S/hygromycin B 
selection for 14 days. Silencing efficiency of each protein 
was monitored by Western blot analysis. On Day 14, cells 
were collected and analyzed by flow cytometry to detect 
the proportion of cells that reactivated EGFP fluorescence 
or lost EGFP signal. All experiments were carried out in 
triplicate. 
calculation of the drug induced rate of HAc loss
To calculate the rate of HAC loss per cell division 
after cell treatment by a single dose of drug, we used the 
equations; 
Eq1 -  [15]
Eq2 - [15]
RNormal is the natural rate of HAC loss per cell 
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division. RDrug is the drug induced rate of HAC loss per 
cell division. P0 is the percentage of EGFP(+) cells when 
cultured under HAC selection. PNormal is the percentage 
EGFP(+) cells when cells are cultured without selection. 
n1 = the number of cell doublings that occurred during 
culturing without selection. PTreated is the percentage 
of EGFP(+) cells at the end of the experiments. n1 is 
the number of cell doublings that occurs during drug 
treatment. As drug treatment was limited to less than 
18 hrs, drug induced HAC loss was limited to a single 
cell cycle, n1 = 1. n2 is the number of cell doublings that 
occurs during the culturing without selection after the drug 
treatment. The doubling time of HT1080 is approximately 
18 hrs.
calculation of the sirNA induced rate of HAc 
loss
We were unable to quantify the number of cell 
divisions that siRNA knockdown impacted. Hence, we 
chose to calculate the average rate of HAC loss per cell 
division for entire duration of the siRNA experiment. The 
equation used was . PN is the percentage 
of EGFP(+) cells at the end of the experiments. n4 is 
the number of cell doublings that occurs during the 
experiment. We estimated this value by counting the size 
of the cell population at three time points. The first time 
point was on day the wells were seeded. The second time 
point was on Day 3, 48 hrs after siRNA transformation. 
After which, 10% of these cells were plated onto a 75cm3 
cell culture flask and left to grow until Day 14. The third 
time point was on Day 14. Cell counts were made using 
a hemocytometer and viability was determined by 5 min 
staining with DRAQ7 (Adcam) at concentration stated by 
the manufacturer and flow cytometry. 
cell viability test
MTS tetrazolium cell viability assays were done 
according to the manufacturer’s instructions (CellTiter 96 
AQueous Assay reagent; Promega). Briefly, the CellTiter 
96 AQueous One Solution Reagent was added to each 
well and incubated at 37 °C for 3 hr. Cell proliferation 
was determined by measuring the absorbance at 490 nm 
using a microplate reader (Molecular Devices). The half-
maximal inhibitory concentration (IC50) was obtained 
from the MTS viability curves using GraphPad Prism 5. 
Experiments were carried out in triplicate.
FIsH analysis with the bAc probe
HT1080 cells were processed for fluorescence in situ 
hybridization (FISH) after drug treatment followed by the 
14 day washout. The probe used for FISH was BAC32-
2-mer(tetO) DNA containing 40 kb of alphoid-tetO array 
cloned into a BAC vector as described previously [16]. 
Specifically, a BAC32-2-mer(tetO) clone contains an 
amplified synthetic alphoid DNA dimer. One monomer of 
this dimer is an alphoid DNA consensus sequence carrying 
the tetO sequence; another monomer is alphoid DNA from 
chromosome 17. This probe is specific to the HAC but 
also gives a low signal with centromeric regions of several 
endogenous chromosomes. BAC DNA was digoxigenin-
labeled using a nick-translation kit with digoxigenin-
11dUTP or biotin16-dUTP (Roche Diagnostics). Images 
were captured as before. The probe was denatured for 5 
min at 95°C and added to the slides, which were incubated 
at 72°C for 2 min before overnight incubation at 39°C. 
After washes with 0.1 × SSC at 65°C followed by a wash 
with 4 × SSC + 0.1% Tween 20 at room temperature, 
standard procedures were used to detect biotinylated 
probes. Slides were mounted with VectaShield and 
screened for the presence or absence of the HAC. Between 
70-150 metaphases were analyzed for each drug treatment. 
Genomic DNA preparation and Pcr analysis
Genomic DNA for PCR analysis was prepared using 
a QIAmp DNA Mini Kit (QIAGEN). Reconstitution of 
the HPRT gene after Cre/lox-mediated recombination 
was determined by specific primers Lox137-R, Rev#6 
and SV40 PA term rev (Supplementary Table S1). Cross 
contamination by hamster chromosomes after HAC 
MMCT transfer from hamster cells to human cells was 
determined by specific primers detecting hamster SINEs: 
Cons B2-F, Ham B2-F and Ham B2-R (Supplementary 
Table S1). PCR products for sequencing were separated 
by agarose gel electrophoresis and gel extracted.
Western blot analysis
siRNA depletion of proteins was confirmed by 
Western blot. The following antibodies were used 
for immunoblotting: Anti-OIP5 (MIS18β) antibody 
(ab168516), Anti-SKA3 antibody (ab175951), Anti-
GAPDH antibody (Cell Signaling).
Fluorescence microplate reader
20,000 cells / well were plated onto a 96 well, 
treated, flat bottom, tissue culture imaging plate, (BD 
falcon, REF 353219) and left to grow overnight with 
80 µg/ml hygromycin B. On the next day, complete 
confluence was achieved, and the cells cultures were 
washed twice with PBS (Life Technologies) with 0.9 mM 
CaCl2 and 0.5 mM MgCl2. Cells were then lysed with 
50 µl of CelLytic Sigma (C2978-50ml) and immediately 
read with a fluorescence microplate reader (Synerg HT 
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Biotech) (Figure 4A)
calculation of the rate of HAc loss using a 
microplate reader
Two cell populations, the HT1080-shGFP-4 cell line 
which contains the HAC (not green) and the HT1080-JH1 
expressing EGFP and without HAC (green) were mixed in 
varying compositions ranging from 0% to 100%. A titter 
curve was generated. The green fluorescence of these 
mixed populations was determined with a microplate 
reader (Figure 4B). The experiment was repeated three 
times, each with 8 replicates. The titration generated a 
linear curve between EGFP intensity and cell populations 
that ranged from 40% to 100% HAC (R2 = -0.9934) 
(Figure 4C). Below 40% HAC-containing cells in 
population, the plate reader was saturated at the settings 
used. 
The average standard deviation from microplate 
reader readings was determined and used to generate two 
parallel lines, one standard deviation above and below the 
mean linear curve. As illustrated in Figure 4D, these two 
curves were used to determine the standard deviation in 
the percentage of green fluorescence cells. Then equations 
Eq1 and Eq2 were used to derive the standard deviation 
of the rate of HAC loss per cell division (Figure 4F). 
T-test was then used to determined how large a difference 
between two values is required to obtain a significant 
difference at P < 0.01 (GraphPad Prism 5) (Figure 4G). 
In addition, by plugging in the known rate of 
natural HAC loss in HT1080, the starting percentage of 
HAC containing cells and all possible value of %HAC in 
a population into Eq1 and Eq2, we determined that the 
lowest percentage of HAC-containing cells for a single 
drug dose was 42%. This is within the detection limit of 
plate reader at the settings used.
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